Do you want to read an article? Please log in or register.
Lung Clearance Index to Track Acute Respiratory Events in School-age Children with Cystic Fibrosis
Pulmonary Fibrosis
RECOMMENDED
Related content
Pulmonary Fibrosis
Respiratory rate in infants with cystic fibrosis throughout the first year of life and association with lung clearance index measured shortly after birth
J Cyst Fibros.
Korten I, Kieninger E, Yammine S, Cangiano G, Nyilas S, Anagnostopoulou P, Singer F, Kuehni CE, Regamey N, Frey U, Casaulta C, Spycher BD, Latzin P; SCILD; BILD study group
doi: 10.1016/j.jcf.2018.07.002.
Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis
Thorax.
Rayment JH, Stanojevic S, Davis SD, Retsch-Bogart G, Ratjen F
doi: 10.1136/
RECOMMENDED
Pulmonary Fibrosis
Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J
Stanojevic S, Davis SD, Perrem L, Shaw M, Retsch-Bogart G, Davis M, Jensen R, Clem CC, Isaac SM, Guido J, Jara S, France L, McDonald N, Solomon M, Sweezey N, Grasemann H, Waters V, Sanders DB, Ratjen FA
doi: 10.1183/13993003.03380-2020
RECOMMENDED
Pulmonary Fibrosis
Longitudinal Course of Clinical Lung Clearance Index in Children with Cystic Fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J
Frauchiger BS, Binggeli S, Yammine S, Spycher B, Krüger L, Ramsey KA, Latzin P
doi: 10.1183/13993003.02686-2020
Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children
PLoS Pathog.
Muhlebach MS, Zorn BT, Esther CR, Hatch JE, Murray CP, Turkovic L, Ranganathan SC, Boucher RC, Stick SM, Wolfgang MC
doi: 10.1371/
ARDS
Mechanical Ventilation
Interleukin-1 Receptor Antagonist Is Associated With Pediatric Acute Respiratory Distress Syndrome and Worse Outcomes in Children With Acute Respiratory Failure
Pediatr Crit Care Med.
Dahmer MK, Quasney MW, Sapru A, Gildengorin G, Curley MAQ, Matthay MA, Flori H, BALI and RESTORE Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network
doi: 10.1097/PCC.
RECOMMENDED
CoughPulmonary Fibrosis
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA
doi: 10.1016/S2213-2600(21)00069-2
Respiratory Tract Infection
Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections
JAMA.
Gerber JS, Ross RK, Bryan M, Localio AR, Szymczak JE, Wasserman R, Barkman D, Odeniyi F, Conaboy K, Bell L, Zaoutis TE, Fiks AG
doi: 10.1001/jama.2017.18715.
RECOMMENDED
Pulmonary Fibrosis
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Chilvers MA, Davies JC, Milla C, Tian S, Han Z, Cornell AG, Owen CA, Ratjen F
doi: 10.1016/S2213-2600(20)30517-8